High-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy but not to noninvasive mechanical ventilation on intubation rate: a systematic review and meta-analysis
Open Access
- 12 July 2017
- journal article
- review article
- Published by Springer Nature in Critical Care
- Vol. 21 (1) , 1-12
Abstract
High-flow nasal cannula oxygen (HFNC) is a relatively new therapy used in adults with respiratory failure. Whether it is superior to conventional oxygen therapy (COT) or to noninvasive mechanical ventilation (NIV) remains unclear. The aim of the present study was to investigate whether HFNC was superior to either COT or NIV in adult acute respiratory failure patients. A review of the literature was conducted from the electronic databases from inception up to 20 October 2016. Only randomized clinical trials comparing HFNC with COT or HFNC with NIV were included. The intubation rate was the primary outcome; secondary outcomes included the mechanical ventilation rate, the rate of escalation of respiratory support and mortality. Eleven studies that enrolled 3459 patients (HFNC, n = 1681) were included. There were eight studies comparing HFNC with COT, two comparing HFNC with NIV, and one comparing all three. HFNC was associated with a significant reduction in intubation rate (OR 0.52, 95% CI 0.34 to 0.79, P = 0.002), mechanical ventilation rate (OR 0.56, 95% CI 0.33 to 0.97, P = 0.04) and the rate of escalation of respiratory support (OR 0.45, 95% CI 0.31 to 0.67, P < 0.0001) when compared to COT. There was no difference in mortality between HFNC and COT utilization (OR 1.01, 95% CI 0.67 to 1.53, P = 0.96). When HFNC was compared to NIV, there was no difference in the intubation rate (OR 0.96; 95% CI 0.66 to 1.39, P = 0.84), the rate of escalation of respiratory support (OR 1.00, 95% CI 0.77 to 1.28, P = 0.97) or mortality (OR 0.85, 95% CI 0.43 to 1.68, P = 0.65). Compared to COT, HFNC reduced the rate of intubation, mechanical ventilation and the escalation of respiratory support. When compared to NIV, HFNC showed no better outcomes. Large-scale randomized controlled trials are necessary to prove our findings. PROSPERO International prospective register of systematic reviews on May 25, 2016 registration no. CRD42016039581 .Keywords
This publication has 50 references indexed in Scilit:
- Heated and Humidified High-Flow Oxygen Therapy Reduces Discomfort During Hypoxemic Respiratory FailureRespiratory Care, 2012
- High-Flow Nasal Interface Improves Oxygenation in Patients Undergoing BronchoscopyCritical Care Research and Practice, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- High-flow nasal oxygen vs high-flow face mask: A randomized crossover trial in extubated patientsJournal of Critical Care, 2010
- Nasal high-flow therapy delivers low level positive airway pressureBritish Journal of Anaesthesia, 2009
- Research in high flow therapy: Mechanisms of actionRespiratory Medicine, 2009
- Going from evidence to recommendationsBMJ, 2008
- Performance of six types of oxygen delivery devices at varying respiratory rates*Anaesthesia, 2007
- Noninvasive Ventilation in Acute Cardiogenic Pulmonary EdemaJAMA, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003